Cullinan Therapeutics, Inc. (CGEM)
CGEM Stock Price Chart
Explore Cullinan Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CGEM price movements and trends.
CGEM Company Profile
Discover essential business fundamentals and corporate details for Cullinan Therapeutics, Inc. (CGEM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
8 Jan 2021
Employees
111.00
Website
https://cullinantherapeutics.comCEO
Nadim Ahmed
Description
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
CGEM Financial Timeline
Browse a chronological timeline of Cullinan Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.80, while revenue estimate is $3.67m.
Earnings released on 7 May 2026
EPS came in at -$0.75 surpassing the estimated -$0.84 by +10.27%.
Earnings released on 10 Mar 2026
EPS came in at -$0.77 surpassing the estimated -$0.80 by +3.75%.
Earnings released on 6 Nov 2025
EPS came in at -$0.77 surpassing the estimated -$0.95 by +18.95%.
Earnings released on 7 Aug 2025
EPS came in at -$1.07 falling short of the estimated -$0.83 by -28.92%.
Earnings released on 8 May 2025
EPS came in at -$0.74 surpassing the estimated -$0.78 by +5.13%.
Earnings released on 27 Feb 2025
EPS came in at -$0.73 surpassing the estimated -$0.75 by +2.67%.
Earnings released on 7 Nov 2024
EPS came in at -$0.69 surpassing the estimated -$0.78 by +11.54%.
Earnings released on 8 Aug 2024
EPS came in at -$0.75 falling short of the estimated -$0.73 by -2.74%.
Earnings released on 15 May 2024
EPS came in at -$0.86 surpassing the estimated -$0.90 by +4.44%.
Earnings released on 14 Mar 2024
EPS came in at -$0.54 surpassing the estimated -$0.96 by +43.75%.
Earnings released on 8 Nov 2023
EPS came in at -$0.91 matching the estimated -$0.91.
Earnings released on 10 Aug 2023
EPS came in at -$0.82 surpassing the estimated -$0.99 by +17.17%.
Earnings released on 11 May 2023
EPS came in at -$1.42 falling short of the estimated -$0.84 by -69.05%.
Earnings released on 9 Mar 2023
EPS came in at -$0.59 surpassing the estimated -$0.65 by +9.23%.
Earnings released on 14 Nov 2022
EPS came in at -$0.54 surpassing the estimated -$0.97 by +44.33%.
Earnings released on 10 Aug 2022
EPS came in at -$2.20 falling short of the estimated $5.47 by -140.22%.
Earnings released on 16 May 2022
EPS came in at -$0.27 surpassing the estimated -$0.61 by +55.74%.
Earnings released on 17 Mar 2022
EPS came in at -$0.74 falling short of the estimated -$0.47 by -57.45%, while revenue for the quarter reached $37.85m .
Earnings released on 9 Nov 2021
EPS came in at -$0.40 surpassing the estimated -$0.42 by +4.76%.
Earnings released on 10 Aug 2021
EPS came in at -$0.36 surpassing the estimated -$0.42 by +14.29%.
CGEM Stock Performance
Access detailed CGEM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
